Microtubule dynamics as a target in oncology.

@article{Risinger2009MicrotubuleDA,
  title={Microtubule dynamics as a target in oncology.},
  author={A. L. Risinger and F. Giles and S. Mooberry},
  journal={Cancer treatment reviews},
  year={2009},
  volume={35 3},
  pages={
          255-61
        }
}
Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors for decades. New, more effective microtubule-targeting agents continue to enter into clinical trials and some, including the epothilone ixapebilone, have been approved for use. In contrast, several other drugs of this class with promising preclinical data were later shown to be ineffective or intolerable in animal models or clinical trials. In… Expand
Tubulin inhibitors: a patent review
TLDR
This article arranges the microtubule-targeting agents that have been published in patent in recent years to help in the investigation of new tubulin binding site and development of novel drug candidate in the future. Expand
LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity
  • M. Qin, Shihong Peng, +10 authors Z. Yi
  • Biology, Medicine
  • The Journal of Pharmacology and Experimental Therapeutics
  • 2015
TLDR
Study proved that LG308 induced mitotic phase arrest and inhibited G2/M progression significantly in LNCaP and PC-3M cell lines in a dose-dependent manner, and these were associated with the upregulation of cyclin B1 and mitotic marker MPM-2 and the dephosphorylation of cdc2. Expand
Drugs that target dynamic microtubules: A new molecular perspective
TLDR
The effects of microtubule‐binding chemotherapeutic agents are reviewed from a new perspective, considering how their mode of binding induces conformational changes and alters biological function relative to the molecular vectors of micro Tubule assembly or disassembly. Expand
Halichondrin B amide acts as tubulin binding agent to exhibit anti-tumor efficacy in hematologic cancers.
TLDR
HCBA appears to be a potent agent to arrest cell cyclin the metaphase and inhibit tubulin polymerization, compared to other existing microtubule destabilizing agents HCBA has good oral bioavailability and lacks MDR cross-resistance acute myelosuppression. Expand
Evaluation of Activity and Combination Strategies with the Microtubule-Targeting Drug Sagopilone in Breast Cancer Cell Lines
TLDR
RNAi screening demonstrated that the sagopilone-induced mitotic arrest can be enhanced by concomitant inhibition of mitotic kinesins, thus suggesting a potential combination therapy of sagopILone with a KIF2C (MCAK) kinesin inhibitor. Expand
Microtubule-binding natural products for cancer therapy.
TLDR
The present review summarizes the development of representative microtubule-binding natural products including agents binding to the colchicine-binding sites, the VINCA alkaloid-binding site, the taxane- binding site and other binding sites. Expand
Recent developments in using plant-derived natural products as tubulin inhibitors for the management of cancer
TLDR
Various aspects of the natural tubulin inhibitors and their role in development of chemotherapeutic agents for cancer treatment are discussed. Expand
Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
TLDR
This Perspective illustrates the different classes of compounds that behave similar to CA-4, analyzes their binding mode to αβ-tubulin according to recently available structural complexes, and includes described approaches to improve their delivery. Expand
Mitosis-targeting natural products for cancer prevention and therapy.
TLDR
This review will focus on natural products that target mitotic process and/or proteins involved in mitotic progression, including taxanes and vinca alkaloids, whose validated target is the spindle microtubules. Expand
An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
TLDR
A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 98 REFERENCES
Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
TLDR
The current preclinical, clinical pharmacokinetic and pharmacodynamic, efficacy and toxicity data of the epothilones are discussed, with a focus on ixabepilone specific. Expand
How do microtubule-targeted drugs work? An overview.
TLDR
It has been argued that microtubules represent the single best cancer target identified to date, and it seems likely that drugs in this class will continue to remain an important chemotherapeutic class of drugs even as more selective chemotherAPEutic approaches are developed. Expand
Mechanisms of Taxol resistance related to microtubules
TLDR
This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modifications, and also at the level of regulatory proteins. Expand
Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198
TLDR
A series of analogues was generated and ENMD-1198 was selected as the lead molecule in this analogue series and is currently in a phase I clinical trial in patients with refractory solid tumors. Expand
The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.
TLDR
The ability of the taccalonolides to overcome clinically relevant mechanisms of drug resistance in vitro and in vivo confirms that they represent a valuable addition to the family of microtubule-stabilizing compounds with clinical potential. Expand
Vinflunine: clinical perspectives of an emerging anticancer agent
TLDR
Noteworthy results from Phase II studies for treatment of non-small cell lung cancer, breast cancer and bladder cancer supported Phase III studies showed important results, and encouraging results of combination use of vinflunine and other biologic agents opened areas to investigate its synergistic or auxiliary role to existing therapies. Expand
Tumour targeting by microtubule-depolymerising vascular disrupting agents
TLDR
Low molecular weight vascular disrupting agents of the microtubule depolymerising family cause marked and selective disruption of the established tumour blood vessel network, resulting in tumour cell necrosis, and constitute a very promising group of novel cancer drugs. Expand
Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
TLDR
The epothilones demonstrate promising antitumor activity in a broad spectrum of taxane-sensitive and -refractory tumors at doses and schedules associated with tolerable side-effects. Expand
Structural basis for the regulation of tubulin by vinblastine
TLDR
The X-ray structure of vinblastine bound to tubulin in a complex with the RB3 protein stathmin-like domain (RB3-SLD) explains vin Blastine-induced tubulin self-association into spiral aggregates at the expense of microtubule growth. Expand
Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines.
TLDR
Results confirm that peloruside A, when added in combination with other microtubule stabilizing agents, acts synergistically to enhance the antimitotic action of the drugs, but also highlight the complexity of drug interactions in intact cells. Expand
...
1
2
3
4
5
...